Nadler and Democrats must zero in on corporate power: Look at prescription drug pricing and megamergers

The midterm election that propelled Democrats to a majority in the House of Representatives revealed voter sentiment on a number of fronts that should inform the House Judiciary Committee’s first 100 days under its likely new leader, New York Rep. Jerrold Nadler (D-NY), including on antitrust and competition policy.

Read More